

CURRICILUM VITAE

January 1, 2008

Michael G. Sension, M.D.
Comprehensive Care Center
HIV Clinical Research
North Broward Hospital District
1101 NW 1st Street
Ft. Lauderdale, FL 33311
Tel: (954) 467-0880 * FAX (954) 525-2030
e-mail: msension@nbhd.org

HIV CLINICAL RESEARCH ROLE:

INVESTIGATOR

FLORIDA LICENSE NUMBER:

ME-0059761

EDUCATION

1991 – 1992	National Institutes of Health Bethesda, MD	Clinical Fellowship Training Infectious Diseases
1988 – 1991	Cornell University New York Hospital Department of Medicine New York, NY	Internship & Residency
1988	John Hopkins School of Medicine Baltimore, MD	M.D.
1983	Wheaton College Wheaton, IL	B.S.

BOARD CERTIFICATION

1994 American Board of Internal Medicine

PROFESSIONAL EXPERIENCE

1993 – Present Medical Director, HIV Clinical Research
North Broward Hospital District
Ft. Lauderdale, FL

PROFESSIONAL EXPERIENCE (continued)

- Principal Investigator for the Division of AIDS Treatment Research Initiative
 - HIV/AIDS Primary Care Practice at the Comprehensive Care Center, North Broward Hospital District.
- 1992 – 1993 Private Practice, Internal Medicine
North Miami Beach and Plantation, FL
- 1990 – 1991 Research in Mycobacterium Tuberculosis and HIV Infection
Dr. Lee Riley, Assistant Professor of Medicine, Division of Internal Medicine, Cornell University Medical Center
New York, NY
- Laboratory-based investigation and pilot study, using polymerase chain reaction to detect M. TB. Infections among HIV and non-HIV infected individuals in Bahia, Brazil.
- 1986 – 1987 Research
Dr. Thomas Quinn, Senior Investigator
Laboratory of Immunoregulation, National Institutes of Health
Bethesda, MD, and Associate Professor of Medicine
John Hopkins University of Medicine
Baltimore, MD
- Studies Included:
- Principal Investigator on a CDC study to evaluate clinical effects of concomitant HIV infection and measles in hospitalized African children, Project SIDA, Kinshasa, Zaire.
 - Evaluation of a rapid latex agglutination assay for HIV antibody detection for use in blood banks in third world countries. John Hopkins Hospital and Project SIDA.
 - Evaluation of a treatment protocol for women with mucopurulent cervicitis.
Baltimore City Public Health Department, Baltimore, MD
- 1985 Research in Preventive Cardiology
Dr. Thomas Pearson, Director
Preventive Cardiology Clinic
John Hopkins Hospital, Baltimore, MD

PROFESSIONAL EXPERIENCE (continued)

Evaluated risk factors for accelerated coronary atherosclerosis
Following heart transplant.

1982 – 1983

Research Assistant
Dr. Robert Loizzi
Professor of Physiology
University of Illinois School of Medicine
Chicago, IL

Participated in study of lactose production in the rat
mammary gland.

SPECIAL PROGRAMS/OVERSEAS EXPERIENCE

1986 – 1987

Clinical and laboratory research with Project SIDA
Kinshasa, Zaire
A joint CDC/NIH project evaluating HIV illness in
Central Africa

1984

Studied rural health care delivery in India, Thailand,
Malaysia, Philippines, Taiwan and South Korea

1983

Worked for six months with a public health team on
Rusinga Island, Kenya

1981

Participated in an orientation program on international health
care at the World Health Organization, Geneva, Switzerland

AWARDS

1985

Dean's Research Award, John Hopkins University, School
Of Medicine, research stipend.

1988

Harold Lamport Biomedical Research Prize, awarded by John
Hopkins University, School of Medicine, for outstanding research
study of HIV infection and measles in hospitalized African
children, Project SIDA, Kinshasa, Zaire

LICENSURE

1989 Board of Medical Examiners, New York
1990 Board of Medical Examiners, Florida

PROFESSIONAL AFFILIATIONS

Florida Medical Association
Broward County Medical Association

ABSTRACTS/PRESENTATIONS

Sension, M., Grinsztejn, B., Molina, J.M., Zavala, I., Antunes, F., Donnelly, A., Agarwal, P., Ledesma, E.

AI424067: Improvement in Lipid Profiles After 12 Weeks of Switching to Atazanavir (ATV) From Boosted or Unboosted Protease Inhibitors (PIs) in Patients With No Previous PI Virologic Failure and Hyperlipidemia at Baseline. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 22-25, 2005.

Sension, M.G., Shen, Y., Bush, L., Zauli, T., Lopez-Guillen, P., Marrero De Leon, S., Rode, R., McMillan, F., Luo, M.P., Tressler, R.

Gastrointestinal Tolerability after PI/NNRTI Substitution with Lopinavir. Presented at the 43rd ICAAC Conference, Chicago, IL. September 14-17, 2003.

Squires, K.E., Thiry, A., Giordano, M., Sension, M., Delfraissy, J.F., Rivero, A., Yakovlev, A.

Atazanavir (ATV) QD vs Efavirenz (EFV) QD with Fixed-Dose ZDV + 3TC BID: Compararison of Antiviral Efficacy and Safety. 48-Week Results from BMS A1424-034 Phase III Pivotal Study. Presented at the 42nd ICAAC Conference, San Diego, California. September 27, 2002.

Sension, M., Thiry, A., Giodano, M.

Absence of insulin resistance through week-24 with Atazanavir once daily and Efavirenze once daily, each with twice daily fixed dose ZDV and 3TC. Presented at the 42nd ICAAC Conference, San Diego, California. September 27, 2002.

Sension, M., Squires, K., Cahn, P., Haas, D., Pantaleo, G., Gatell, J., Percival, L., Piliero, P., Sanne, I., Wood, R., Phanuphakp, P., Shelton, S., Lazzarin, A., Thiry, A., Kelleher, T., Giordano, M., Schnittman, S.M.

Change in total cholesterol (as per NCEP ATP III) from baseline at 48-weeks following treatment with Atazanavir (ATV) or comparator protease inhibitors (PIs). Presented at the 42nd ICAAC Conference, San Diego, California. September 27, 2002.

ABSTRACTS/PRESENTATIONS (continued)

Mcomsey, G., Lonergan, T., Fisher, R., Sension, M., Hoppel, C., Williams, V., Ross, L., Hernandez, J.

Improvements in Lipoatrophy (LA) are observed after 24 weeks when Stavudine (d4T) is replaced by either Abacavir (ABC) or Zidovudine (ZDV). Presented at the 9th Conference on Retroviruses and Opportunistic Infections.. Seattle, WA, February 24-28, 2002.

Sension, M., Harley, W., DeJesus, E., Jiang, P., Garrett, L., McMillan, F., Clark, P., Japour, J.

Final Analysis of a 24-week Randomized, Controlled, Open-label Evaluation of Adherence and Convenience of Continuing Indinavir versus Switching to Ritonavir/Indinavir 400 MG/400 MG BID (The Nice Study). Presented at the 1st IAS Conference on HIV pathogenesis and Treatment. Buenos Aires, Argentina, July 8-11, 2001.

Harley, W., DeJesus, E., Pistole, M., Sension, M., Garrett, L., Nettler, S., Jiang, P., Rode, R., Ashfaf, T., McMillan, F., Japour, J.

A 24-Week Randomized, Controlled, Open-Label Evaluation of Adherence and Convenience of Continuing Indinavir Versus Switching to Ritonavir/Indinavir 400 mg/400 mg BID (The NICE Study). Presented at the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 4-8, 2001.

Sension, M., Bellos, N., Johnson, J., Sepulveda, G., Santana, J., Ames, M., Goodwin, D. Efficacy and Safety of Switch to 3TC 300 mg QD versus Continued 3TC 150 mg BID in Subjects with Virologic Suppression on Stable 3TC/d4T/PI Therapy (COLA4005): Final 24-Week Results. Presented at the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 4-8, 2001.

Cohen, C., Sension, M., Macko, J., Somogyi, M., Siemon-Hryczk, P.

Response to Highly Active Antiretroviral Therapy (HAART) Following Prior Treatment with Saquinavir Soft Gel Capsules (SQV-SGC). Presented at the 40th ICAAC Conference, Toronto, Ontario, Canada, September 17-20, 2000.

Cohen, C., Kessler, H., Hunt, S., Sension, M., Farthing, C., Conant, M., Jacobson, S., Nadler, J., Verbiest, W., Hertogs, K., Ames, M., Rinehart, A., Graham, N.

Phenotypic Resistance Testing Significantly Improves Response to Therapy (tx): Analysis of a Randomized Trial (VIRA3001). Presented at the 4th International Workshop on HIV Drug Resistance & Treatment Strategies, Sitges, Spain, June 12-16, 2000.

Cohen, C., Hunt, S., Sension, M., Farthing, C., Conant, M., Jacobson, C., Nadler, J., Verbiest, W., Hertogs, K., Ames, A., Rinehart, E., Graham, N.

Open-label, Randomized Comparison of Phenotypic Resistance Testing (Antivirogram; AVG) Guided Therapy (Tx) Switch vs Standard of Care (SOC) in

ABSTRACTS/PRESENTATIONS (continued)

- Subject Failing First PI-containing HAART Regimen. Presented at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 30 – February 3, 2000.
- Giordano, M.F., Beall, G., Sension, M., Yakim, E., Parenti, D., Keiser, P. Ritonavir 400 mg BID Compared with Ritonavir 600 mg BID in Protease Inhibitor-Naïve Subjects. Presented at the 7th European Conference on Clinical Aspects and Treatment of HIV Infection, October, 1999.
- Zolopa, A., Tebas, P., Gallant, J., Keiser, P., Sension, M., Smith, P., Gathe, J., Flamm, J., Hawkins, T., Nadler, J., Shafer, R., Henry, K. The Efficacy of Ritonavir (RTV) Saquinavir (SQV) Antiretroviral Therapy (ART) in Patients who failed Nelfinavir (NFV): a Multicenter Clinical Cohort Study. Presented at the 39th ICAAC Conference, San Francisco, CA, September, 26-29, 1999.
- Conant, M., Brown, S., Cohen, C., Henry, K., Hunt, S., Sension, M., Stein, A., Stryker, R., Thompson, M., Stoffels, P., Verbiest, W., Van Den Broeck, R., Hertogs, K., Larder, B. An Epidemiological Prospective Survey Assessing the Prevalence of HIV-1 Drug Resistance in 230 HIV-1 Positive Antiretroviral-Naïve Patients from the USA. Presented at the 39th ICAAC Conference, San Francisco, CA, September 26-29, 1999.
- Ruane, R., Farthing, C., Goodgame, J., Hauptman, S., Sension, M., Hoffman, R., Manning, L., Jiang, P., McMillan, F., Rode, R., Mayer, S., Sun, E. Ritonavir/Indinavir 400/400 mg BID Combination Treatment is Preferred by HIV-Infected Patients Previously Receiving Indinavir 800 mg q8h. Presented At the International Symposium on HIV, Leukemia and Opportunistic Infections, Marrakech, Morocco, May 1999.
- Giordano, M.F., Beall, G., Sension, M., Yakim, E., Parenti, D., Keiser, P. Low-dose Ritonavir Compared with Standard-dose Ritonavir in Protease Inhibitor-naïve Subjects. Presented at the 12th International Conference on Antiviral Research, Jerusalem, Israel, May 21-26, 1999.
- Slater, L., Sension, M., Feinberg, J., Poblete, R., Siemon-Hryczyk, P., Pilson, R., Palleja, S. Fortovase BID Regimens in HIV-1 Infected Patients Combination with 2 NucleosideAnalogos or with Nelfinavir plus 1. NA. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31 – February 4, 1999.

ABSTRACTS/PRESENTATIONS (continued)

Kessler, H., Follansbee, S., Sension, M., Johnson, J., Hetherington, S.
Safety and Efficacy of Abacavir in an Open-label Program. Presented as a poster
At the IDSA 36th annual meeting, Denver, CO, November 12–15, 1998.

Sension, M., Elion, R., Richardson, B., Becker, M.
I-218, An Open-label Study to Assess the 49 Week Efficacy and Safety of BID
VIRACEPT (Nelfinavir mesylate) Combined with 2 NRTS's in HIV Infected
Treatment-naïve Patients. Presented as a poster at the 38th ICAAC Conference,
San Diego, CA, September 24-28, 1998.

Sension, M. et al.
Saquinavir Soft Gel Capsule (SGC) in Combination with AZT and 3TC in
Treatment Naïve Patients. Presented as a poster at the 38th ICAAC Conference,
San Diego, CA, September 24-28, 1998.

Graham, K.K., Beeler, L., Sension, M., Renae, S.
Interventions and Patient Outcome from a Pharmacist-based HIV Medication
Adherence. Referral Clinic. Presented at the 12th World AIDS Conference,
Geneva, Switzerland, June 28 - July 3, 1998.

Sension, M., Farthing, C., Palmer-Pattison, T., Pilson, R., Siemon-Hryczyk, P.
FORTOVASE™ (Saquinavir Soft Gel Capsule; SQV-SGC) in Combination
with AZT and 3TC in Antiretroviral-naïve HIV-1 Infected Patients. Presented at
the 5th Conference of Retrovirus and Opportunistic Infections, Chicago, IL,
February 1-5, 1998.

Sension, M., Elion, R., Farthing, C., Currier, J., Lindquist, C., Richardson, B., Becker, M.
Open-label Pilot Studies to Assess the Safety and Efficacy of BID-dosing
Regimens of VIRACEPT (Nelfinavir mesylate) Combined with NRTI's in HIV-
Infected Treatment Naïve Patients. Presented at the 5th Conference of Retrovirus
and Opportunistic Infections, Chicago, IL, February 1-5, 1998.

Sension, M., Farthing, C., Churchill, H., Chang, H., Siemon-Hryczyk, P., Pilson, R.,
Fisher, L.
Soft Gel Capsule Saquinavir (SGC SQV) in Combination with AZT and 3TC in
Antiretroviral-naïve HIV-1 Infected Patients. Infectious Disease Society of
America, September, 1997, San Francisco, CA.

Sension, M., Siemon-Hryczyk, P., Pilson, R.
Sanquinavir Soft Gel Capsule (SGC) in Combination with AZT and 3TC in
Treatment Naïve Patients. Presented as a poster at the 6th European Conference
On Clinical Aspects and Treatment of HIV-Infection, Hamburg, Germany,
October, 1997.

ABSTRACTS/PRESENTATIONS (continued)

Sension, M., Huber, K., Palmer-Pattison, T.

An Open-label Study to Assess the Safety and Efficacy of BID-dosing of VIRACEPT (Nelfinavir Mesylate) Combined with Stavudine (d4T) + Lamivudine (3TC) in HIV Infected Treatment-naïve Patients. Presented as A poster at the 6th European Conference on Clinical Aspects and Treatment of HIV-infection, Hamburg, Germany, October, 1997.

Sension, M., Farthing, C., Siemon-Hryczyk, P.

Saquinavir in Soft Gel Capsule (SGC) in Combination with AZT and 3tC in Treatment Naïve Patients. Presented as a poster at the 37th ICAAC Conference, Toronto, Ontario, Canada, September – October 1997.

Powderly, W., Sension, M., Conant, M., Stein, A., Clendeninn, N.

The Efficacy of VIRACEPT™ (Nelfinavir mesylate, NFV) in Pivotal Phase II/III Double-blind Randomized Controlled Trials as Monotherapy and in Combination with d4T or AZT/3TC. Presented as a poster at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January, 1997.

Kalathoor, S., Sinclair, J., Andron, L., Sension, M., High, K.

Combination therapy with Stavudine and Didanosine. Presented at a poster at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January, 1997.

Mole, L., Holodniy, M., Lalezari, J., Banach, M., Sension, M., Schnittman, S.

The Relationship Between Blood and Lymph Node Viral Load. Presented as a Poster at the 3rd Conference on Retroviruses and Opportunistic Infections. Washington, D.C., January, 1996.

Markowitz, L., Nzilambi, N., Driskell, J., Sension, M., Rovira, E., Neiberg, P., et al
Vitamin A Level and Mortality Among Hospitalized Measles Patients, Kinshasa, Zaire. Presented as a poster at the 28th Conference Agents and Chemotherapy, Los Angeles, CA., October, 1998.

Quinn, T., Francis, H., Kline, R., DiUma, M., Sension, M., Rovira, E., Neiberg, P. et al
Evaluation of a Latex Agglutination Assay Using Recombinant Envelope Polypeptides III International Conference on AIDS, Washington, D.C., June, 1987. Abstracts Volume THP. 19(166).

Sension, M., Nzila, N., Dumb, M., Ryder, R. Quinn, T. Linnan, M., et al

Does Concomitant HIV Infection and Measles Infection in African Children Lead to Increased Morbidity and Mortality? Presented as a poster at the Scientific Sessions of the III International Conference on AIDS, Washington, D.C., June, 1987. Abstract Volume THP, 159(190).

ABSTRACTS/PRESENTATIONS (continued)

Markakis, M., Sension, M., Vitalis, S., Becker, D., Pearson, T.
Risk Factors for Accelerated Coronary Atherosclerosis Following Heart Transplant. Presented at the annual meeting of the Preventive Cardiology Academic Awardees, Bethesda, MD, April 17-18, 1986.

Becker, D., Markakis, M., Vitalis, S., Sension, M., Baughman, K., Pearson, T.
Risk Factors for Accelerated Coronary Atherosclerosis Following Heart Transplant: Primary Prevent in a Tertiary Setting. Presented at the Scientific Sessions of the American College of Cardiology, Atlanta, GA, March, 1986.
J. Amer. Col. Card., 7:9A, 1986

PUBLICATIONS

Squires, K., Lazzarin, A., Gatell, J., Powderly, W.G., Pokrovskiy, V., Delfraissy, J.F., Jemsek, J., Rivero, A., Rozenbaum, W., Schrader, S., Sension, M., Vibhagool, A., Thiry, A., Giordano, M.
Comparison of Once-Daily Atazanavir with Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV. Journal of AIDS. August 2004, Volume 36, No. 5.

Wood, R., Phanuphak, P., Cahn, P., Pokrovskiy, V., Rozenbaum, W., Pantaleo, G., Sension, M., Murphy, R., Mancini, M., Kelleher, T., Giordano, M.
Long-Term Efficacy and Safety of Atazanavir with Stavudine and Lamivudine in Patients Previously Treated with Nelfinavir or Atazanavir. Journal of AIDS. June 2004, Volume 36, No.2

Sension, M.G.
Initial Therapy for Human Immunodeficiency Virus: Broadening the Options. HIV Clinical Trials, March-April 2004, Volume 5, Number 2.

Sension, M.G., Bellos, N.C., Johnson, J., Sepulveda, G.E., DeJesus, E., Santana, J.L., Ames, M.H., Goodwin, S.D.
Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients. HIV Clinical Trials. Sept-Oct 2002, Volume 3, Number 5.

Saag, M.S., Tebas, Pablo, Sension, M., Conant, M., Myers, R., Chapman, S.K., Anderson, R., Clendeninn, N.
To Evaluate the Safety and Antiretroviral Activity of Nelfinavir Mesylate at Two Doses as Part of a Combination Regimen in HIV-infected, Antiretroviral-Naïve Patients. AIDS 2001, Vol 15, No 15.

PUBLICATIONS (continued)

- Sension, M., Farthing, C., Shaffer, A., Graham, E., Siemon-Hryczyk, P., Pilson, R.
Challenges of Antiretroviral Treatment in Transient and Drug-Using Populations:
The Sun Study. AIDS Patient Care and STD's. Vol. 15, Number 3.
- Hafner, R., Cohn, J.A., Wright, D.J., Dunlap, N.E., Egorin, M.J., Enama, M.E., Muth, K.,
Peloquin, C.A., Mor, N., Heifets, L.B. and the DATRI 008 Study Group, Sension, M.,
et al.
Early Bactericidal Activity of Isoniazid in Pulmonary Tuberculosis: Optimization
Of Methodology, Am J Respir Crit Care Med 1997, Vol. 156, pp 918-923.
- Markowitz, L., Nzilambi, N., Driskell, J., Sension, M., Rovira, E., Nieburg, P., et al
Vitamin A Levels and Mortality Among Hospitalized Measles Patients, Kinshasa,
Zaire. Journal of Tropical Pediatrics. Vol. 35, 1989, pp 109-112.
- Quinn, T, Riggan, C., Kline, R., Francis, H., Mulanga, K., Sension, M., Fauci, A
Rapid Latex Agglutination Assay using Recombinant Envelope Polypeptide for
Detection of Antibody to the Human Immunodeficiency Virus. JAMA, Vol. 26,
No.4, 1998, pp 510-513.
- Sension, M., Quinn, T., Markowitz, L., Linnan, M., Jones, T., Francis, H., et al
Measles in Hospitalized African Children with Human Immunodeficiency Virus
(letter). Am. J. Dis. Child, Vol. 142, No 12, 1988, pp 1271-1272.
- Becker, D., Markakis, M., Sension, M., Vitalis, S., Baughman, K., Swank, et al.
Hyperlipidemia in Heart Transplant Recipients. Transplantation Proceedings,
Vol. 44, No 2, 1987, pp 323-325.